CMO to scale up bio anti-cancer drug

Amsterdam-based SynCo Bio Partners has expanded its reach to Japan, where it will manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.

The contract manufacturer will first consultant with the unnamed drug maker on in-house process development. The developed process will then be transferred to SynCo's Amsterdam facility and scaled-up, prior to GMP manufacturing of a live, biotherapeutic-based anticancer drug for Phase I clinical trials. The scale-up effort will include fermentation, formulation and aseptic filling.

SynCo announced a month ago a deal to produce Versartis's lead candidate, a GLP-1 analog for monthly dosing to treat type 2 diabetes. As with the Japanese deal, the CMO is further developing the existing production process. It is also optimizing the manufacturing process to increase yields for cGMP production.

- here's the SynCo release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.